A previous study indicated that treatment with the GLP-1 agonist liraglutide (subcutaneously at a dose gradually titrated from 0.6 to 3 mg) in bipolar and mood disorder depression patients could result in an improvement in cognitive function and an alleviation of depressive pathological symptoms ( Considering this evidence, increasing neurogenesis in the brain through the GLP-1 pathway may provide a novel approach for improving depressive-like behavior in patients with depression
Human evidence is anecdotal
Theo di k v ngng s dng nu c phn ng bt thng
Check newtropin.com for schedule updates
Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 trial results demonstrating 25% weight loss in half of people with #obesity
A growing number of adults are looking for safe and effective alternatives to traditional growth hormone therapy, and as such, interest in peptides like CJC-1295 have increased Google search trends shows consistent growth over the last five years